menu
About Us
Classes Of Business
HMO Reinsurance
Provider Excess Of Less
Medical Reinsurance
Employer Stop Loss
Client Captive Programs
Cell & Gene Therapy
Cost Containment
News
Contact Us
News
FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma
on
October 27, 2022
(updated January 23, 2023)
| Category:
News
FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma
Click here to download PDF
